Sarepta Therapeutics reported $699.39M in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
Amgen USD 51.61B 250M Sep/2026
BioCryst Pharmaceuticals USD 395.61M 209K Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Capricor Therapeutics USD 3.38M 0 Mar/2025
Daiichi Sankyo JPY 499.93B 75M Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Gilead Sciences USD 23.82B 17M Sep/2026
Incyte USD 28.42M 994K Jun/2026
Insmed USD 544.86M 1.35M Sep/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Moderna USD 3.55B 2.95B Sep/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60B 498M Sep/2026
PTC Therapeutics USD 536.27M 749K Sep/2026
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 16.28B 1.63B Sep/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
Tectonic Therapeutic USD 17K 26K Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026